Copyright
©The Author(s) 2018.
World J Hepatol. Oct 27, 2018; 10(10): 670-684
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.670
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.670
No. | Trade name | Generic name with doses |
1 | Sovaldi | Sofosbuvir 400 mg |
2 | Olysio | Simeprevir 150 mg |
3 | Daklinza | Daclatasvir 30 mg/60 mg/90 mg |
4 | Harvoni | Ledipasvir 90 mg/Sofosbuvir 400 mg |
5 | Viekira Pak | 1 d pack contains Paritaprevir 75 mg/Ombitasvir 12.5 mg/Ritonavir 50 mg tablet × 2 and Dasabuvir 250 mg tablet × 2 |
6 | Viekira XR | Extended release tablet contains Dasabuvir 200 mg/ombitasvir 8.33 mg/Paritaprevir 50 mg/Ritonavir 33.33 mg |
7 | Technivie | Ombitasvir 12.5 mg/Paritaprevir 75 mg/Ritonavir 50 mg |
8 | Epclusa | Sofosbuvir 400 mg/ Velpatasvir 100 mg |
9 | Zepatier | Elbasvir 50 mg/ Grazoprevir 100 mg |
10 | Mavyret | Glecaprevir 100 mg/ Pibrentasvir 40 mg |
11 | Vosevi | Sofosbuvir 400 mg/Velpatasvir 100 mg/Voxilaprevir 100 mg |
- Citation: Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684
- URL: https://www.wjgnet.com/1948-5182/full/v10/i10/670.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i10.670